The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single‐tablet regimen in the expanding spectrum of fixed‐dose combination therapy for HIV

Two-drug vs . three-drug combinations for HIV-1: Do we have enough data to make the switch?

(2019) S Moreno et al.   HIV MEDICINE

Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort

(2019) JM Llibre et al.   HIV MEDICINE

Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana

(2019) Rebecca Zash et al.   NEW ENGLAND JOURNAL OF MEDICINE

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

(2019) Paul E Sax et al.   CLINICAL INFECTIOUS DISEASES

Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial

(2018) Alejandro Arenas-Pinto et al.   CLINICAL INFECTIOUS DISEASES

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

(2018) Norah A. Terrault et al.   HEPATOLOGY

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

(2018) Josep M Llibre et al.   LANCET

Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials

(2018) A. Antinori et al.   Scientific Reports

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study

(2018) Lene Ryom et al.   Lancet HIV

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial

(2018) Eric S Daar et al.   Lancet HIV

Clinical Impact of Virological Failure and Resistance Analysis Definitions used in Pivotal Clinical Trials of Initial Antiretroviral Treatment: A Systematic Review

(2018) Josep M. Llibre et al.   AIDS REVIEWS

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2018) Michael S. Saag et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure

(2018) Raza M. Alvi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception

(2018) Rebecca Zash et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

(2018) Pedro Cahn et al.   LANCET

Brief Report

(2017) José R. Arribas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2017) Frank A. Post et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Brief Report

(2017) François Raffi et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial

(2017) Paul E Sax et al.   LANCET

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

(2017) Joel Gallant et al.   LANCET

Improved life expectancy of people living with HIV: who is left behind?

(2017) Ingrid T Katz et al.   Lancet HIV

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

(2017) Adam Trickey et al.   Lancet HIV

Lack of Clinically Relevant Effect of Bictegravir (BIC, B) on Metformin (MET) Pharmacokinetics (PK) and Pharmacodynamics (PD)

(2017) Joseph Custodio et al.   Open Forum Infectious Diseases

Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection

(2016) Rosa Lombardi et al.   DIGESTIVE AND LIVER DISEASE

Neuropsychiatric Effects of HIV Antiviral Medications

(2016) Glenn J. Treisman et al.   DRUG SAFETY

Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection

(2016) Roger Bedimo et al.   HIV CLINICAL TRIALS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

(2016) Anthony Mills et al.   LANCET INFECTIOUS DISEASES

Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy

(2016) Sumanth Karamchand et al.   MEDICINE

How to predict the risk of fracture in HIV?

(2016) Michael T. Yin et al.   Current Opinion in HIV and AIDS

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments

(2016) Amit C. Achhra et al.   Current HIV/AIDS Reports

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients

(2015) Isabelle Poizot-Martin et al.   PLoS One

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study

(2015) Nina Friis-Møller et al.   European Journal of Preventive Cardiology

Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection

(2014) Merel M. Heuft et al.   AIDS

Association Between Efavirenz as Initial Therapy for HIV-1 Infection and Increased Risk for Suicidal Ideation or Attempted or Completed Suicide

(2014) Katie R. Mollan et al.   ANNALS OF INTERNAL MEDICINE

Cross-sectional Comparison of the Prevalence of Age-Associated Comorbidities and Their Risk Factors Between HIV-Infected and Uninfected Individuals: The AGEhIV Cohort Study

(2014) J. Schouten et al.   CLINICAL INFECTIOUS DISEASES

An update on the pharmacogenomics of metformin: progress, problems and potential

(2014) Jennifer N Todd et al.   PHARMACOGENOMICS

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy

(2013) Zara Shubber et al.   AIDS

Single-tablet regimens in HIV: does it really make a difference?

(2013) Isabel Aldir et al.   CURRENT MEDICAL RESEARCH AND OPINION

A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection

(2013) Nathan Clumeck et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Association of tenofovir exposure with kidney disease risk in HIV infection

(2012) Rebecca Scherzer et al.   AIDS

Comparison of Changes in Bone Density and Turnover with Abacavir‐Lamivudine versus Tenofovir‐Emtricitabine in HIV‐Infected Adults: 48‐Week Results from the ASSERT Study

(2010) Hans‐Jürgen Stellbrink et al.   CLINICAL INFECTIOUS DISEASES

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

(2009) Kimberly Y Smith et al.   AIDS

Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations

(2009) H N Kim et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study

(2009) Signe Westring Worm et al.   JOURNAL OF INFECTIOUS DISEASES